Mistletoe (Viscum album), a plant often associated with winter traditions, is earning global recognition for its role in cancer research. In integrative oncology, mistletoe extract is being investigated not as a cure but as a powerful complementary therapy to support patients undergoing conventional cancer treatment.
Decades of European research, particularly in Germany, have explored mistletoe's potential to enhance immune function, reduce tumor-related symptoms, and improve quality of life. Mistletoe contains biologically active compounds—such as lectins and viscotoxins—that exhibit immune-modulating and anti-tumor properties. These compounds may help stimulate the body’s natural defenses, regulate inflammation, and even slow cancer cell growth in certain cases.
Clinical studies suggest that subcutaneous mistletoe injections can reduce the side effects of chemotherapy and radiation, such as fatigue, loss of appetite, and weakened immunity. Many patients report better physical and emotional resilience when mistletoe is used alongside standard care.
Importantly, mistletoe therapy is not a standalone cancer treatment. It is used as part of a holistic, patient-centered approach that values both evidence-based medicine and supportive care. Research continues worldwide to better understand its effects across different cancer types, with promising findings in breast, lung, and gastrointestinal cancers.
Organizations like ABNOBA GmbH are leading the development of high-quality mistletoe preparations for clinical use. With ongoing research and patient feedback driving innovation, mistletoe is becoming a valuable tool in integrative cancer care—bridging natural medicine with modern science.
Always consult your healthcare provider before beginning any complementary therapy.
